Cargando…
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
Objective: Interferon-free therapy for hepatitis C virus (HCV) infection is costly, and therefore patients with advanced fibrosis are prioritized. Although coupled with considerable side effects, a large proportion of genotype 2/3 infected patients achieve a sustained virological response (SVR) foll...
Autores principales: | Waldenström, Jesper, Färkkilä, Martti, Rembeck, Karolina, Norkrans, Gunnar, Langeland, Nina, Mørch, Kristine, Pedersen, Court, Rauning Buhl, Mads, Nieminen, Urpo, Nuutinen, Hannu, Alsiö, Åsa, Holmström, Lars, Jungnelius, Rolf, Lund, Katarina, Rubensson, Anders, Torell, Erik, Westin, Johan, Lagging, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4732462/ https://www.ncbi.nlm.nih.gov/pubmed/26418670 http://dx.doi.org/10.3109/00365521.2015.1087588 |
Ejemplares similares
-
Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
por: Alsiö, Åsa, et al.
Publicado: (2012) -
Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3
por: Rembeck, Karolina, et al.
Publicado: (2012) -
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
por: Waldenström, Jesper, et al.
Publicado: (2016) -
Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013) -
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
por: Rembeck, Karolina, et al.
Publicado: (2012)